Immunocore Holdings Plc ((IMCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunocore Holdings Plc is conducting a Phase 1 clinical study titled ‘A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers.’ The study aims to evaluate the safety and efficacy of IMC-P115C, a half-life extended ImmTAC targeting PRAME, in treating advanced PRAME-positive cancers. This research is significant as it explores new treatment avenues for patients with these specific cancer types.
The intervention being tested is IMC-P115C, administered as an intravenous infusion. It is designed to target PRAME, a cancer-associated antigen, potentially offering a novel therapeutic option for patients with advanced stages of the disease.
The study follows an interventional design with a sequential assignment model. There is no masking involved, meaning all participants and researchers are aware of the treatment being administered. The primary purpose of the study is treatment-focused, aiming to assess the therapeutic potential of IMC-P115C.
Key dates for the study include its start date on August 26, 2025, and the last update on September 3, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
The market implications of this study could be significant for Immunocore Holdings Plc, potentially boosting its stock performance and investor interest if the results are positive. The study’s outcomes could also influence the competitive landscape in the oncology sector, particularly for treatments targeting PRAME-positive cancers.
The study is currently ongoing, with further details available on the ClinicalTrials portal.